收费全文 | 8139篇 |
免费 | 757篇 |
国内免费 | 69篇 |
耳鼻咽喉 | 88篇 |
儿科学 | 147篇 |
妇产科学 | 235篇 |
基础医学 | 1131篇 |
口腔科学 | 140篇 |
临床医学 | 829篇 |
内科学 | 1234篇 |
皮肤病学 | 106篇 |
神经病学 | 517篇 |
特种医学 | 416篇 |
外科学 | 1045篇 |
综合类 | 451篇 |
一般理论 | 3篇 |
预防医学 | 823篇 |
眼科学 | 221篇 |
药学 | 592篇 |
2篇 | |
中国医学 | 79篇 |
肿瘤学 | 906篇 |
2022年 | 71篇 |
2021年 | 141篇 |
2020年 | 76篇 |
2019年 | 115篇 |
2018年 | 121篇 |
2017年 | 120篇 |
2016年 | 100篇 |
2015年 | 171篇 |
2014年 | 209篇 |
2013年 | 301篇 |
2012年 | 408篇 |
2011年 | 420篇 |
2010年 | 284篇 |
2009年 | 246篇 |
2008年 | 362篇 |
2007年 | 362篇 |
2006年 | 379篇 |
2005年 | 351篇 |
2004年 | 342篇 |
2003年 | 345篇 |
2002年 | 306篇 |
2001年 | 263篇 |
2000年 | 261篇 |
1999年 | 271篇 |
1998年 | 104篇 |
1997年 | 93篇 |
1996年 | 78篇 |
1995年 | 71篇 |
1994年 | 63篇 |
1993年 | 65篇 |
1992年 | 142篇 |
1991年 | 170篇 |
1990年 | 163篇 |
1989年 | 149篇 |
1988年 | 139篇 |
1987年 | 147篇 |
1986年 | 133篇 |
1985年 | 156篇 |
1984年 | 103篇 |
1983年 | 97篇 |
1982年 | 58篇 |
1981年 | 58篇 |
1980年 | 63篇 |
1979年 | 88篇 |
1978年 | 60篇 |
1977年 | 57篇 |
1975年 | 60篇 |
1974年 | 57篇 |
1973年 | 68篇 |
1972年 | 55篇 |
Background
Adjuvant cisplatin-based chemotherapy (ACT) after resection of stages II-IIIA non-small cell lung cancer (NSCLC) modestly increased survival in several clinical trials. This study evaluated the subsequent impact of those trials on ACT use in clinical practice.Methods
Patients who underwent lobectomy or more extensive lung resection without induction chemotherapy for pathologically confirmed N1 positive NSCLC between 2000 and 2012 were reviewed. Referrals to medical oncology, oncologist recommendations for ACT, and initiation of ACT were evaluated. Because major trials supporting ACT were published in 2004 and 2005, analysis was stratified into two eras: 2000-2005 and 2006-2012.Results
During the study period, 272 patients met inclusion criteria (110 in the 2000-2005 cohort, 162 in the 2006-2012 cohort). Referrals to medical oncology increased from 74.5% (n=82) in the 2000-2005 cohort to 90.1% (n=146) in the 2006-2012 cohort (P=0.002). Due to lack of referral or missed appointments, 35.5% (n=39) of the 2000-2005 patients and 17.9% (n=32) of the 2006-2012 patients did not have a documented conversation with an oncologist regarding ACT. The proportion of patients recommended for ACT increased from 61% (n=50) to 81.5% (n=119) between the eras (P<0.001). Of patients recommended for chemotherapy, 14% (7/50) in 2000-2005 and 13.4% (16/119) in 2006-2012 declined ACT (P=0.666).Conclusions
Publication of supporting evidence increased recommendations for ACT but did not change the percentage of patients who ultimately agreed to receive ACT. Additional research is needed to better understand patient decision-making in this situation. 相似文献Method: Memory clinic staff with limited previous experience of group therapy were trained to lead a 10-week group therapy intervention called ‘Living Well with Dementia’. Fifty-eight participants, all of whom had received a diagnosis of Alzheimer's disease, vascular or Lewy body dementia within the previous 18 months, were randomised to receive either the intervention or treatment as usual (waiting-list control). Data collection occurred at baseline, within two weeks after the intervention finished and at 10-week follow-up.
Results: The study met its recruitment targets, with a relatively low attrition rate for the intervention arm. The acceptability of the intervention and research methods was examined qualitatively and will be reported on elsewhere. For the primary outcome, measure of quality of life in Alzheimer's disease (QoL-AD), and secondary outcome, self-esteem, there was some evidence of improvement in the intervention group compared to the control group. There was, also, evidence of a reduction in cognitive functioning in the treatment group compared to the control. Such reported differences should be treated with caution because they are obtained from a pilot and not a definitive study.
Conclusion: This pilot study succeeded in collecting data to inform a future definitive cost effectiveness clinical trial of Living Well with Dementia group therapy. 相似文献